ALB and neoplasm: We developed a strategy to extend the rIL-12 T<sub>1⁄2</sub> that depends on binding albumin <i>in vivo</i> to target tumor tissue, using single-chain rIL-12 linked to a fully human albumin binding (F<sub>H</sub>AB) domain (SON-1010).